Plasma catecholamine release-inhibitory peptide catestatin in patients with essential hypertension
Lei Meng1, Xiao-jin Ye, Wen-hui Ding
1Department of Cardiology, Peking University First Hospital, Beijing, People's Republic of China.
Insights
Plasma catestatin is elevated in essential hypertension patients. The catestatin to norepinephrine ratio is lower in patients with left ventricular hypertrophy, suggesting catestatin
Area of Science:
- Cardiovascular Research
- Endocrinology
- Hypertension Studies
Background:
- Catestatin is crucial for regulating blood pressure and cardiac function.
- Essential hypertension is a common cardiovascular condition.
- Left ventricular hypertrophy is a significant complication of hypertension.
Purpose of the Study:
- To investigate plasma catestatin levels in essential hypertension.
- To explore the relationship between catestatin and left ventricular hypertrophy.
Main Methods:
- Enzyme-linked immunosorbent assay (ELISA) for plasma catestatin.
- High-performance liquid chromatography for plasma norepinephrine.
- Echocardiography for left ventricular hypertrophy assessment.
Main Results:
- Elevated plasma catestatin and norepinephrine in essential hypertension patients.
- Reduced catestatin/norepinephrine ratio in essential hypertension.
- Lower catestatin/norepinephrine ratio in hypertensive patients with left ventricular hypertrophy.
Conclusions:
- Plasma catestatin is elevated in essential hypertension.
- The catestatin/norepinephrine ratio is diminished in left ventricular hypertrophy.
- Catestatin may play a role in hypertension and left ventricular hypertrophy development.
Background:
Catestatin plays an important role in the adjustment of blood pressure and cardiac function. We investigated levels of plasma catestatin in essential hypertension and the relationship between catestatin and left ventricular hypertrophy.
Methods:
Plasma was collected from 136 patients with essential hypertension and 61 healthy controls. Plasma catestatin was measured by enzyme-linked immunosorbent assay (ELISA). Plasma norepinephrine was measured by high-performance liquid chromatography. All patients underwent echocardiography, measurement of fasting blood glucose, body mass index (BMI) and lipid levels.
Results:
Plasma levels of catestatin and norepinephrine were significantly higher in patients with essential hypertension than in normal controls (both P<0.01). The ratio of catestatin to norepinephrine was significantly lower in patients with essential hypertension than in normal controls (P<0.01). In patients with essential hypertension, plasma norepinephrine level was significantly higher in patients with than without left ventricular hypertrophy (P<0.01). Plasma catestatin level was lower, but not significantly, in patients with than without left ventricular hypertrophy. The ratio of catestatin to norepinephrine was significantly lower in patients with than without left ventricular hypertrophy (P<0.01).
Conclusion:
Plasma catestatin is elevated in patients with essential hypertension. The ratio of catestatin to norepinephrine was lower in patients with left ventricular hypertrophy. Catestatin might participate in the development of hypertension and left ventricular hypertrophy.
Related Concept Videos
01:17Antihypertensive Drugs: Action of β1 Blockers
01:30Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors
01:17Hormonal Regulation of Blood Pressure
Epinephrine and Norepinephrine
The adrenal medulla releases epinephrine and norepinephrine, catecholamines that enhance and extend the sympathetic or "fight or flight" physiological response. These hormones escalate heart rate and the force of contraction while...
01:25Antihypertensive Drugs: Direct Renin Inhibitors
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
01:30Antihypertensive Drugs: Angiotensin II Receptor Blockers